Artemisinin-based combination therapy for ... - The Cochrane Library

(Continued)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Efficacy: Total Failure
(P. falciparum)
Day 28 PCR adjusted
Efficacy: Total Failure
(P. falciparum)
Day 28 PCR un adjusted-
Vivax efficacy: P.
vivax parasitaemia
Transmission
potential: Gametocyte
carriage day
14
Harms: Serious adverse
events (including
deaths)
Harms: Early vomiting
Assumed risk Corresponding
risk
Amodiaquine plus
sulfadoxinepyrimethamine
Artesunate plus
amodiaquine
- - - 2346
(6)
- - - 4220
(8)
No of participants
(studies)
Quality of the evidence
(GRADE)
⊕
very low 1,2,3,4,5
⊕
very low 1,4,5,6,7,8
- - - - Not reported
38 per 1000 22 per 1000
(6 to 77)
17 per 1000 1 per 1000
(6 to 18)
RR 0.57
(0.16 to 2.02)
RR 0.61
(0.36 to 1.03)
894
(3)
4200
(7)
⊕
very low 4,9,10,11,12
⊕⊕⊕
moderate 13,14,15
- - - - Not reported
*The assumed risk is the mean risk from the studies included in this review, calculated as the number of patients in the control
groups with the event divided by the total number of patients in control groups. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Footnotes
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
262